Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490697 | 0.82 | ALDH1A1 (0.45) | MAPK1NPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL25426510 | 0.82 | ALDH1A1 (0.54) | MAPK1NPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL9708647 | 0.77 | ALDH1A1 (0.51) | MAPK1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8769880 | 0.76 | CTRB1 (0.57) | MAPK1NPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL8658530 | 0.76 | EPHX2 (0.48) | MAPK1NPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL19966273 | 0.76 | ALDH1A1 (0.54) | MAPK1NPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL7454009 | 0.75 | ELANE (0.47) | MAPK1RAB9AALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL10859364 | 0.75 | ALDH1A1 (0.61) | MAPK1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17948794 | 0.74 | LMNA (0.56) | MAPK1SMN1; SMN2ALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL15447362 | 0.74 | ALDH1A1 (0.45) | MAPK1ALDH1A1L3MBTL1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1313730-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018378-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MAPK1 2772/4885NPC1 3753/4885GAA 3102/4885 |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | CMA1, CTRL, TPSD1 | MAPK1 1233/4885NPC1 1986/4885GAA 134/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MAPK1 2772/4885NPC1 3753/4885GAA 3102/4885 |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | MAPK1 2772/4885NPC1 3753/4885GAA 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.